TWEET by @CellCentric
Team CellCentric will be at ESMO 2022, 9-13 Sept, Paris. Advancing inobrodib, first in class p300/CBP inhibitor drug, to treat specific cancers. pic.twitter.com/t88Iar9ir8
TWEET by @CellCentric
USAN have confirmed a new drug name (stem) for bromodomain inhibitors of p300/CBP. CellCentric’s inobrodib is first in class! pic.twitter.com/mTJpOEhUfH
TWEET by @CellCentric
Great to have many of the core team together; working with our partner clinicians, hospitals, consultants and CROs, to advance inobrodib, our pioneering p300/CBP inhibitor. pic.twitter.com/FS0xWo7zoM
TWEET by @CellCentric
Our clinical development leadership at ASCO. Pioneering p300/CBP inhibition to treat specific cancers. Inobrodib now in Phase II. pic.twitter.com/StoCgrcCvN
TWEET by @CellCentric
CellCentric’s clinical & scientific leadership will be as ASCO 2022. We continue to advance our pioneering p300/CBP inhibitor to treat specific cancers. #ASCO22 pic.twitter.com/SciCvWzilS
TWEET by @CellCentric
It’s international clinical trials day. Inobrodib is in Phase II to treat specific cancers in the UK, US and EU. Thank you patients, clinicians, clin ops team! pic.twitter.com/kHwD7bDV2Z
